UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No.     )*

BioAmber Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

09072Q 106

(CUSIP Number)

Sarah Lafaye    

Sofinnova Partners

17 rue de Surene

75008 Paris

France

(+33) 1 53 05 41 13

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 9, 2013

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ¨

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Item 1. Security and Issuer

(a) This statement on Schedule 13D relates to the common stock, par value $0.01 per share (the “Common Stock”) of BioAmber Inc., a Delaware corporation (the “Issuer”).

(b) 1250 Rene Levesque West, Suite 4110, Montreal, Quebec, Canada H3B 4W8.

Item 2. Identity and Background

(a) The persons and entities filing this Schedule 13D are Sofinnova Capital VI FCPR (“SC VI”), Sofinnova Partners SAS, a French corporation (“SP SAS”), and Denis Lucquin (“Lucquin”), Antoine Papiernik (“Papiernik”), Rafaèle Tordjman (“Tordjman”) and Monique Saulnier (“Saulnier”), the managing partners of SP SAS (collectively, the “Listed Persons” and together with SC VI and SP SAS, the “Filing Persons”).

(b) The address of the principal place of business for each of the Filing Persons is Sofinnova Partners, 17 rue de Surène, 75008 Paris, France.

(c) The principal occupation of each of the Filing Persons is the venture capital investment business. Each of the Listed Persons is employed at the offices of Sofinnova Partners, 17 rue de Surène, 75008 Paris, France.

(d) During the last five years, none of the Filing Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) During the last five years, none of the Filing Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f) SC VI is a French FCPR. SP SAS is a French Corporation. Lucquin, Papiernik, Tordjman and Saulnier are French citizens.

Item 3. Source and Amount of Funds or Other Consideration.

On June 22, 2009, SC VI purchased from the Issuer a secured convertible promissory note and warrants to purchase 208,950 shares of Common Stock for approximately $4,000,000 of consideration paid out of the working capital of SC VI. The note matured on September 30, 2009 and was converted on October 22, 2009 into 696,500 shares of Common Stock. The warrants have an exercise price of $5.74 per share and a term that expires June 22, 2019.

On October 22, 2009, SC VI also purchased from the Issuer 696,500 shares of Common Stock for approximately $4,000,000 of consideration paid out of the working capital of SC VI.

On November 23, 2010, SC VI purchased an unsecured convertible promissory note from the Issuer for $2,932,242 of consideration paid out of the working capital of SC VI. On April 15, 2011 the note was converted into 278,005 shares of Common Stock and warrants to purchase 69,475 shares of Common Stock at an exercise price of $10.55 with a 10-year term. Pursuant to adjustment provisions of the warrants, SC VI was issued warrants to purchase an additional 1,342 shares of Common Stock at the same exercise price with the same 10-year term in connection with the closing of the Issuer’s IPO (as defined below).

Also on April 15, 2011, SC VI purchased 932,050 shares of Common Stock at a price per share of $10.55, or $9,830,198.20 in the aggregate, paid out of the working capital of SC VI.

On November 4, 2011, SC VI purchased 214,165 shares of Common Stock at a price per share of $28.49, or $6,100,643 in the aggregate, paid out of the working capital of SC VI.

On May 14, 2013, at the closing of the Issuer’s initial public offering (the “IPO”), SC VI purchased 880,000 units (the “Units”) at a purchase price of $10.00 per Unit, for total consideration of $8,800,000. Each Unit consisted of one share of Common Stock and one warrant to purchase half of one share of Common Stock at an exercise price of $11.00 per whole Common Share (the “IPO Warrants”). The Units were purchased by SC VI using its working capital. The 440,000 shares of Common Stock underlying the IPO Warrants are not exerciseable until August 8, 2013, and therefore are not included in the total 4,082,547 shares reported above.

Item 4. Purpose of Transaction.

The shares of Common Stock acquired by SC VI in the IPO (described in Item 3 above) were acquired solely for investment purposes. The Response to Item 3 above is incorporated into this Item 4 by reference.

As of the date of this Schedule 13D, and except as provided herein, none of the Filing Persons have any plan or proposal relating to or that would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer; (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; (c) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; (d) any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or terms of directors or to fill any existing vacancies on the Board of Directors of the Issuer; (e) any material change in the present capitalization or dividend policy of the Issuer; (f) any other material change in the Issuer’s business or corporate structure; (g) any changes in the Issuer’s charter, by-laws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (h) a class of securities of the Issuer being delisted from a national securities exchange or ceasing to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (i) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act; or (j) any action similar to those enumerated above.

Item 5. Interest in Securities of the Issuer.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Lock-Up Agreement

In connection with the IPO, SC VI agreed that, subject to certain exceptions, without the prior written consent of Credit Suisse Securities (USA) LLC, Société Générale and Barclays Capital Inc. on behalf of the underwriters of the IPO, SC VI will not, during the period ending November 5, 2013 (as such period may be extended under certain circumstances), offer, sell, contract to sell, announce the intention to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of any shares of Common Stock, or any options or warrants to purchase any shares of Common Stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock, whether now owned or hereafter acquired, owned directly by SC VI (including holding as a custodian) or with respect to which SC VI has beneficial ownership within the rules and regulations of the SEC, or exercise any right with respect to the registration of such shares, or demand or cause to be filed any registration statement in connection therewith, under the Securities Act, as amended (the “Securities Act”).

Shareholders’ Agreement

On April 15, 2011, the Issuer and SC VI, together with other holders of the Issuer’s Common Stock, options and warrants, entered into an Amended and Restated Shareholders’ Agreement, which was further amended on November 4, 2011, February 6, 2012 and May 2, 2013 (as amended, the “Shareholders’ Agreement”). The Shareholders’ Agreement provides registration rights, as well as customary rights provided to major investors including pre-emptive rights, rights of first refusal, co-sale rights with respect to stock transfers, rights regarding the election of investor designees to our board of directors, drag-along rights in the event of a sale of the Company, information rights and other similar rights. All of these rights, other than the registration rights, terminated upon the completion of the IPO. The registration rights are described below.

Registration Rights

SC VI and other holders of an aggregate of approximately 8.5 million shares of the Issuer’s Common Stock, including shares of Common Stock issuable upon exercise of warrants that were in existence prior to the date of the IPO, are entitled to rights with respect to the registration of these shares under the Securities Act for resale to the public (the “Registrable Securities”). All of these rights are provided under the terms of the Shareholders Agreement and include demand registration rights, piggyback registration rights and Form S-3 and Form F-3 registration rights, in each case as described below. The registration rights will terminate for any particular holder with registration rights at such time following the IPO when all securities held by that holder may be sold pursuant to Rule 144 under the Securities Act.

Piggyback Registration Rights. If the Issuer decides to register any of its securities under the Securities Act, either for its own account or for the account of a security holder or holders, the holders of registration rights, including SC VI, are entitled to prompt notice of the registration and are entitled to include their shares of Common Stock in the registration. These piggyback registration rights do not apply with respect to a registration statement relating to an employee benefit plan or to a corporate reorganization or other transaction under Rule 145 of the Securities Act.

Demand Registration Rights. At any time after 180 days from the effective date of the IPO, subject to certain limitations, the holders of a majority of the Registrable Securities then outstanding (the “Initiating Holders”) have the right to demand that the Issuer file a registration statement covering the registration of at least 10% of the Registrable Securities then outstanding and having an aggregate price to the public of not less than $15.0 million. The Issuer will not be required to effect a registration if (1) the Issuer has effected three registrations that have been declared effective and have remained effective until the holders have completed the distribution related thereto, (2) the Issuer’s board of directors, in its reasonable judgment, determines that it would be detrimental to the Issuer and its stockholders for such registration statement to be effected at such time, in which case the Issuer has the right to defer such filing for up to 90 days following receipt of the demand request from the holders and (3) the Initiating Holders propose to dispose of Registrable Securities that are immediately registrable on Form S-3 or Form F-3, as applicable.

Form S-3 and Form F-3 Registration Rights. At any time after the Issuer becomes eligible to file a registration statement on Form S-3 or Form F-3, any holder or holders of Registrable Securities for which a Form S-3 or Form F-3 is available may require the Issuer to file such a registration statement having an aggregate price to the public of not less than $1.0 million. The Issuer is not obligated to file more than two Form S-3 or Form F-3 registration statements in any twelve-month period. In addition, the Issuer is not obligated to effect a registration if (1) a Form S-3 or Form F-3, as applicable, is not available for such offering by the holder or holders, (2) the Issuer’s board of directors, in its reasonable judgment, determines that it would be detrimental to the Issuer and its stockholders for such registration statement to be effected at such time, in which case the Issuer has the right to defer such filing for up to 90 days following receipt of the Form S-3 or Form F-3 demand request from the holder or holders and (3) with respect to a particular jurisdiction, the Issuer would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance.

Expenses of Registration. The Issuer generally is required to bear the expenses of all registrations, including the expense of a single special counsel to the holders of each registration not to exceed $75,000 per registration. However, the Issuer will not be required to pay for underwriting discounts and commissions or expenses in connection with the exercise of demand and piggyback registration rights if the request is subsequently withdrawn by the holders of a majority of the Registrable Securities, subject to limited exceptions.

The foregoing summary of the Shareholders’ Agreement is qualified in its entirety by reference to the text of the Amended and Restated Shareholders Agreement and the First, Second and Third Amendments thereto, which are filed herewith as Exhibits 1 , 2, 3 and 4, respectively, and are incorporated herein by reference.

The information provided and incorporated by reference in Items 3, 4 and 5 is hereby incorporated by reference herein.

Other than as described in this Schedule 13D, to the best of the Filing Persons’ knowledge, there are no other contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 and between such persons and any person with respect to any securities of the Issuer.

Item 7. Material to Be Filed as Exhibits.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 21, 2013

EXHIBIT INDEX

EXHIBIT 5

LOCK-UP AGREEMENT

BioAmber Inc.

Lock-Up Agreement

April 10, 2013

Credit Suisse Securities (USA) LLC,

Société Générale,

Barclays Capital Inc.

As representatives of the several Underwriters

named in Schedule I hereto

11 Madison Avenue

New York, New York 10010-3629

29, boulevard Haussmann,

75009 Paris, France

745 Seventh Avenue

New York, New York 10019

Ladies and Gentlemen:

The undersigned understands that this Lock-Up Agreement is being delivered to Credit Suisse Securities (USA) LLC, Société Générale and Barclays Capital Inc. in connection with the proposed underwriting agreement (the “Underwriting Agreement”) to be entered into by the representatives of the underwriters on behalf of the several underwriters named in Schedule I to such agreement (collectively, the “Underwriters”), with BioAmber Inc., a Delaware corporation (the “Company”), providing for a public offering (the “Offering”) of units, consisting of one share of common stock, par value $0.01 per share, of the Company (the “Common Stock”) and one warrant to purchase half of one share of Common Stock, pursuant to a Registration Statement on Form S-1 to be filed with the Securities and Exchange Commission (the “SEC”).

In consideration of the agreement by the Underwriters to offer and sell the Shares, and of other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the undersigned agrees that, during the period commencing on the date of this Lock-Up Agreement and continuing for 180 days after the date set forth on the final prospectus used to sell the Shares pursuant to the Underwriting Agreement (the “Lock-Up Period”), the undersigned will not offer, sell, contract to sell, announce the intention to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of any shares of Common Stock of the Company, or any options or warrants to purchase any shares of Common Stock of the Company, or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock of the Company, whether now owned or hereafter acquired, owned directly by the undersigned (including holding as a custodian) or with respect to which the undersigned has beneficial ownership within the rules and regulations of the SEC (collectively the “Undersigned’s Shares”), or exercise any right with respect to the registration of any of the Undersigned’s Shares, or demand or cause to be filed any registration statement in connection therewith, under the Securities Act of 1933, as amended, without, in each case, the prior written consent of Credit Suisse Securities (USA) LLC, Société Générale and Barclays Capital Inc. The foregoing restriction is expressly agreed to preclude the undersigned from engaging in any hedging or other transaction which is designed to or which reasonably could be expected to lead to or result in a sale or disposition of the Undersigned’s Shares even if such shares would be disposed of by someone other than the undersigned. Such prohibited hedging or other transactions would include without limitation any short sale or any purchase, sale or grant of any right (including without limitation any put or call option) with respect to any of the Undersigned’s Shares or with respect to any security that includes, relates to, or derives any significant part of its value from such shares. If the undersigned is an officer or director of the Company, the undersigned further agrees that the foregoing provisions shall be equally applicable to any Company-directed Shares the undersigned may purchase in the Offering.

If the undersigned is an officer or director of the Company, (i) Credit Suisse Securities (USA) LLC, Société Générale and Barclays Capital Inc. agree that, at least three business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of shares of Common Stock, Credit Suisse Securities (USA) LLC, Société Générale and Barclays Capital Inc. will notify the Company of the impending release or waiver, and (ii) the Company has agreed in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service at least two business days before the effective date of the release or waiver. Any release or waiver granted by the Credit Suisse Securities (USA) LLC, Société Générale and Barclays Capital Inc. hereunder to any such officer or director shall only be effective two business days after the publication date of such press release. The provisions of this paragraph will not apply if (a) the release or waiver is effected solely to permit a transfer not for consideration and (b) the transferee has agreed in writing to be bound by the same terms described in this letter to the extent and for the duration that such terms remain in effect at the time of the transfer.

Notwithstanding the foregoing, the undersigned may (A) transfer the Undersigned’s Shares (i) as a bona fide gift or gifts, (ii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, provided that any such transfer shall not involve a disposition for value, (iii) as a distribution without consideration to members, limited partners or stockholders of the undersigned, (iv) to the undersigned’s affiliates or to any investment fund or other entity controlled or managed by the undersigned, provided in the case of any transfer pursuant to clauses (i) through (iv), that (x) the donee, trustee, distribute or transferee execute an agreement stating that the such person is receiving and holding such capital stock subject to the provisions of this Lock-Up Agreement and there shall be no further transfer of such capital stock except in accordance with this Lock-Up Agreement, (y) any such transfer shall not involve a disposition for value and (z) no filing under Section 16 of the Exchange Act of 1934, as amended (the “Exchange Act”), shall be required or shall be voluntarily made in any public filing or report; (B) enter into or amend a trading plan pursuant to Rule 10b5-1 under Exchange Act, for the transfer of shares of Common Stock, provided that such plan does not provide for the transfer of Common Stock during the Lock-Up Period and no public announcement or filing under the Exchange Act regarding the entrance into or amendment of such plan shall be required of or voluntarily made by or on behalf of the undersigned or the Company during the Lock-Up Period; (C) exercise any options to purchase shares of Common Stock or convert any convertible security into Common Stock, provided that (x) the shares of Common Stock issued upon such exercise shall be subject to the restrictions of this Lock-Up Agreement, (y) neither the exercise nor the change in the undersigned’s beneficial ownership of the Company’s securities resulting from such exercise, if any, is required to be reported in any public report or filing with the SEC or otherwise and (z) neither the undersigned nor the Company otherwise voluntarily effects any public filing or reports regarding such exercise or the change in the undersigned’s beneficial ownership of the Company’s securities resulting from such exercise, if any; or (D) enter into any transaction relating to shares of Common Stock or any security convertible into Common Stock acquired in open market transactions after the completion of the Offering, provided that no filing under Section 16 of the Exchange Act shall be required or shall be voluntarily made during the Lock-Up Period. For purposes of this Lock-Up Agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin. The undersigned now has, and, except as contemplated by clauses (i) through (vi) above, for the duration of this Lock-Up Agreement will have, good and marketable title to the Undersigned’s Shares, free and clear of all liens, encumbrances, and claims whatsoever. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the Undersigned’s Shares except in compliance with the foregoing restrictions.

The undersigned understands that the Company and the Underwriters are relying upon this Lock-Up Agreement in proceeding toward consummation of the Offering. The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement. The undersigned further understands that this Lock-Up Agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives, successors, and assigns.

This Lock-Up Agreement shall automatically terminate upon the earliest to occur, if any, of: (1) Credit Suisse Securities (USA) LLC, Société Générale and Barclays Capital Inc. advising the Company in writing that they have determined not to proceed with the Offering, or the Company advising Credit Suisse Securities (USA) LLC, Société Générale and Barclays Capital Inc. in writing that it has determined not to proceed with the Offering and, if a registration statement relating thereto has been filed with the Securities and Exchange Commission, the Company has withdrawn such registration statement, in each case, prior to the execution of the Underwriting Agreement, (2) termination of the Underwriting Agreement before the sale of any shares of Common Stock to the Underwriters and (3) December 31, 2013 if, and only if, the Offering has not been consummated by that date.

This Lock-Up Agreement shall be governed by and construed in accordance with the laws of the State of New York.

[Signature Page Follows]

EXHIBIT 6

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock of BioAmber Inc. and further agree that this agreement be included as an exhibit to such filing. Each party to the agreement expressly authorizes each other party to file on its behalf any and all amendments to such statement. Each party to this agreement agrees that this joint filing agreement may be signed in counterparts.

In evidence whereof, the undersigned have caused this Agreement to be executed on their behalf this 20th day of May, 2013.

[signature page follows]

In evidence whereof, the undersigned have caused this Joint Filing Agreement to be executed on their behalf this 21st day of May, 2013.

EXHIBIT 9

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Jean-Francois Huc and Andrew P. Ashworth, and each of them individually, and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act which is necessary, proper or desirable to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that any such attorney-in-fact, or any such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 13 or Section 16 of the Exchange Act or the rules or regulations thereunder. The undersigned hereby agrees to indemnify each attorney-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to such attorney-in fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any instruments, certificates and documents pursuant to Section 13 and 16 of the Exchange Act or the rules or regulations thereunder with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of May 21, 2013.

EXHIBIT 10

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Jean-Francois Huc and Andrew P. Ashworth, and each of them individually, and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act which is necessary, proper or desirable to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that any such attorney-in-fact, or any such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 13 or Section 16 of the Exchange Act or the rules or regulations thereunder. The undersigned hereby agrees to indemnify each attorney-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to such attorney-in fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any instruments, certificates and documents pursuant to Section 13 and 16 of the Exchange Act or the rules or regulations thereunder with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of May 21, 2013.

EXHIBIT 11

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Jean-Francois Huc and Andrew P. Ashworth, and each of them individually, and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:

The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act which is necessary, proper or desirable to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that any such attorney-in-fact, or any such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that each of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 13 or Section 16 of the Exchange Act or the rules or regulations thereunder. The undersigned hereby agrees to indemnify each attorney-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to such attorney-in fact.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file any instruments, certificates and documents pursuant to Section 13 and 16 of the Exchange Act or the rules or regulations thereunder with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of May 21, 2013.